Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Dror Bashan | $401,836 | $279,491 | $190,015 | $169,017 | $0 | $0 | $126,575 | $1,166,934 |
| President and Chief Executive Officer | ||||||||
| Eyal Rubin | 240,576 | 181,208 | 183,393 | 31,452 | 0 | 0 | 195,832 | 832,461 |
| Senior Vice President and Chief Financial Officer | ||||||||
| Yaron Naos | 232,784 | 90,115 | 77,804 | 79,826 | 0 | 0 | 95,240 | 575,769 |
| Senior Vice President, Chief Operating Officer | ||||||||
| Gilad Mamlok | 133,919 | 0 | 0 | 229,729 | 0 | 0 | 41,577 | 405,225 |
| Senior Vice President and Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Dror Bashan | $1,166,934 | — | — | — |
| Eyal Rubin | 832,461 | — | — | — |
| Yaron Naos | 575,769 | — | — | — |
| Gilad Mamlok | 405,225 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Dror Bashan | RSU | 178,750 | — | $321,750 |
| Yaron Naos | RSU | 69,753 | — | 125,555 |
| Dror Bashan | Option | 140,625 | 1.03 | — |
| Dror Bashan | Option | 311,667 | 1.64 | — |
| Gilad Mamlok | Option | 548,158 | 1.45 | — |
| Yaron Naos | Option | 63,750 | 1.03 | — |
| Yaron Naos | Option | 58,333 | 1.1 | — |
| Yaron Naos | Option | 45,833 | 1.64 | — |
The primary goals of the Compensation Committee are to attract and retain the most talented and dedicated executives possible, to tie annual and long-term cash and stock incentives to achievement of specified performance objectives, and to align executives’ incentives with stockholder value creation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | — |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-25 | 28,368,614 | 6,683,937 | 197,602 | 80.93% | Passed |
| 2025 | 2025-06-26 | 16,440,449 | 7,488,809 | 384,202 | 68.7% | Passed |
| 2024 | 2024-06-27 | 17,038,394 | 9,884,021 | 410,790 | 63.29% | Passed |
| 2022 | 2022-06-30 | 16,953,326 | 3,466,524 | 218,590 | 83.02% | Passed |
| 2020 | 2020-06-07 | 14,550,187 | 4,306,979 | 180,011 | 77.16% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-25 | 80.93%a |
| 2025 | 2025-06-26 | 68.7%b |
| 2024 | 2024-06-27 | 63.29%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | — |
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Protalix BioTherapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Protalix BioTherapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Option | 2025 | John Rademacher | $1,000,000 | $6,500,050 | $0 | $1,665,000 | $9,266,330 |
| 2 | Stock | 2025 | James Hillebrand | 875,000 | 656,250 | 218,750 | 1,487,500 | 3,380,337 |
| 3 | Protalix BioTherapeutics | 2025 | Dror Bashan | 401,836 | 190,015 | 169,017 | 0 | 1,166,934 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Protalix BioTherapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Option | 111% | PSU 60 · RSU 40 | No | Pearl Meyer |
| Stock | 200% | PSU 75 · Options 25 | No | Aon's Human Capital Solutions |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Dror Bashan | DEF 14A | 2026-04-30 | 0001104659-26-053016 | Section “Executive Compensation”. As printed: 1,166,934. Filing ↗ |
| 2 | Section 01, Eyal Rubin | DEF 14A | 2026-04-30 | 0001104659-26-053016 | Section “Executive Compensation”. As printed: 832,461. Filing ↗ |
| 3 | Section 01, Yaron Naos | DEF 14A | 2026-04-30 | 0001104659-26-053016 | Section “Executive Compensation”. As printed: 575,769. Filing ↗ |
| 4 | Section 01, Gilad Mamlok | DEF 14A | 2026-04-30 | 0001104659-26-053016 | Section “Executive Compensation”. As printed: 405,225. Filing ↗ |
| 5 | Section 06, 2026 vote | Form 8-K | 2026-06-25 | 0001104659-26-077790 | Item 5.07 · say-on-pay result. As reported: 80.93% (votes for as printed: 28,368,614). Filing ↗ |
| 6 | Section 06, 2025 vote | Form 8-K | 2025-06-26 | 0001558370-25-008922 | Item 5.07 · say-on-pay result. As reported: 68.7% (votes for as printed: 16,440,449). Filing ↗ |
| 7 | Section 06, 2024 vote | Form 8-K | 2024-06-28 | 0001558370-24-009567 | Item 5.07 · say-on-pay result. As reported: 63.29% (votes for as printed: 17,038,394). Filing ↗ |
| 8 | Option, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001140361-26-013825 | CEO total compensation as printed in Option's own proxy. As printed: 9,266,330. Filing ↗machine: r2 · c25 · span 1114074–1114083 |
| 9 | Stock, Section 10b CEO total | DEF 14A | 2026-03-12 | 0001437749-26-007879 | CEO total compensation as printed in Stock's own proxy. As printed: 3,380,337. Filing ↗machine: r3 · c32 · span 991255–991264 |
| 10 | Protalix BioTherapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053016 | CEO total compensation as printed in Protalix BioTherapeutics's own proxy. As printed: 1,166,934. Filing ↗ |
| 11 | Section 10a, Stock reciprocity | DEF 14A | — | 0001437749-26-007879 | Stock's most recent proxy was read; its disclosed peer group does not include Protalix BioTherapeutics. Filing ↗ |
| 12 | Section 10a, Option reciprocity | DEF 14A | — | 0001140361-26-013825 | Option's most recent proxy was read; its disclosed peer group does not include Protalix BioTherapeutics. Filing ↗ |